OBJECTIVES The aim of this study was to compare the efficacy of amphilimus-eluting stents (AES) with that of
P atients with diabetes mellitus (DM) remain at high risk of in-stent restenosis and adverse cardiovascular events despite the use of drug-eluting stents (DES) (1, 2) . Second-generation DES provide superior safety and efficacy results compared with first-generation DES (3, 4) . However, stent thrombosis and restenosis rates remain an issue of continued concern (5).
The amphilimus-eluting stent (AES) is a thirdgeneration DES devoid of polymer that elutes sirolimus formulated with an amphiphilic carrier (so-called amphilimus) from laser-dug wells on the stent's abluminal surface (6) . This technology might be associated with a high efficacy in patients with DM (7) . The aim of this trial was to assess the efficacy of the AES in patients with DM compared with the cobalt chromium everolimus-eluting stent with nonerodible polymer (EES).
METHODS STUDY DESIGN AND PATIENT SELECTION.
A full description of the trial was previously reported (8) . The sirolimus is formulated with a mixture of longchain fatty acids (so-called amphilimus) to act as a carrier and to control the drug release. Thus, 65% to 70% of the drug is released within the first 30 days, and the remainder is completely eluted by 90 days (9) .
The EES (Xience Prime or Xience Expedition coronary stent system, Abbott Vascular, Abbott Park, Illinois) is a balloon-expandable cobalt chromium L605 stent, with an 81-mm strut thickness. The whole stent is coated (conformal configuration) with a thin (7.8 mm), nonerodible and biocompatible fluorinated copolymer. The polymer is designed to release 80% of the drug (everolimus, 100 mg/cm 2 ) by 30 days and the remainder by 120 days (10) .
STUDY PROCEDURES. Procedures were performed according to standard techniques. Successful predilation was mandatory before randomization.
Post-dilation was encouraged by protocol, although it OCT data were also analyzed at a central core lab overlapped stents or side-branch take off were not considered for analysis. For totally occluded vessels that were not associated with stent thrombosis, it was estimated that the entire length of the stent was filled with NI hyperplasia (13) .
STATISTICAL ANALYSIS. The study sample size was determined based on the primary endpoint of 9-month NI volume obstruction, assuming no difference in mean. On the basis of previously published data on a wide population, we expected a NI volume obstruction of 15.0% for the EES and an SD of 10.7% (14) . The noninferiority margin was set at 5.3% (equaling 35% of the expected primary endpoint in the EES group) (8).
Given these assumptions, 102 subjects would have provided an 80% power to demonstrate the noninferiority. To account for dropout and to ensure enough OCT data, w112 patients were eventually required.
For continuous variables, differences between groups were evaluated by Student t test, whereas for discrete variables, chi-square or Fisher exact test was used. Normality of angiographic and OCT endpoint Table 2) .
Angiographic success was achieved in all cases.
QUANTITATIVE ANGIOGRAPHIC CHARACTERISTICS.
A total of 100 patients (103 lesions) underwent angiographic follow-up surveillance, with paired data analyzable for 99 patients (102 lesions). Angiographic characteristics are shown in Table 3 . After stent implantation, reference vessel diameter, minimal lumen diameter, and acute gain were similar in both groups. at 9 months had analyzable OCT data (1 OCT scan in the EES group could not be performed due to OCT system failure, and 1 OCT scan in the AES group was not analyzable due to poor image quality). Analyzable OCT data were available in all cases of TLR before any intervention was performed.
OCT results are presented in Table 4 There was 1 case of definite late stent thrombosis (104 days after implantation) in the EES group. This patient was on dual antiplatelet therapy with clopidogrel, and the cause of the stent thrombosis was related to severe restenosis. There was 1 unwitnessed death 13 days after AES implantation that was judged to be a probable stent thrombosis. One patient in the AES group underwent unscheduled coronary angiography due to progressive angina, which showed severe stenosis of a jailed diagonal branch (<2.5 mm) with a patent study stent; the operator decided to perform kissing balloon angioplasty, and therefore, although the study stent was widely patent, it was judged to be a target lesion revascularization.
DISCUSSION
In the RESERVOIR study, we compared the efficacy of a novel elution technology (drug-elution from laser-dug wells and formulation with an amphiphilic carrier) with the classic elution from a durable polymer in patients with DM. Our findings showed that AES were not inferior to EES in patients with DM.
The concept of a polymer-free DES is attractive because the lack of polymer may avoid late events caused by chronic inflammation associated with some durable polymers (15) . However, despite the use of microporous surfaces, direct application of the drug Lesions with $5% of uncovered and malapposed struts to the metallic surface of the stent led in most cases to fast elution, which was clinically translated to an impaired antirestenotic efficacy, even with the use of higher doses of drug than polymer-based DES (16, 17) .
By contrast, our study shows that drug-elution can be performed in a timely manner by formulating the drug with an amphiphilic carrier in the absence of a polymer. In addition, elution from reservoirs allows almost all of the drug to be delivered to the vessel wall, as opposed to DES with polymer in a conformal configuration (in which a significant proportion of the drug is released to the blood) (9) . To the best of our knowledge, this is the first study to show noninferiority of a polymer-free DES compared with the cobalt chromium EES, which is the DES with the most robust evidence of safety and efficacy in patients with DM (18, 19) .
Our study showed a significant interaction between the metabolic control assessed by the HbA 1c
and the stent type effect, with a significant reduction of NI hyperplasia in the AES group in poorly controlled patients. In patients with DM, as glucose uptake and oxidation are impaired, the heart is forced Barcelona, Spain. E-mail: rafaromaguera@gmail.com. 
